Efficacy of adaptogens in patients with Long COVID-19: a randomized, quadruple-blind, placebo-controlled trial
Karosanidze I, Kiladze U, Kirtadze N, Giorgadze M, Amashukeli N
Published in Pharmaceuticals
Methodology
Randomized, quadruple-blind, placebo-controlled trial in 100 patients with at least three Long COVID symptoms receiving Chisan/ADAPT-232, a fixed combination of Rhodiola, Eleutherococcus and Schisandra, or placebo for two weeks
Key Findings
The adaptogen combination shortened the duration of fatigue by about one day and pain by about two days in half of patients.
Conclusions
Small symptomatic benefit from a three-herb combination; Schisandra cannot be isolated.
Limitations
Two-week intervention; combination product; modest effect sizes; single country.
Supplements Studied
Chisan decreased the duration of fatigue and pain for one and two days, respectively, in 50% of patients.
Outcomes Measured
Chisan decreased the duration of fatigue and pain for one and two days, respectively, in 50% of patients.
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.